| INVITED REVIEW |
|
| Year : 2014 | Volume
: 16
| Issue : 3 | Page : 348-353 |
|
|
Radium-223 in metastatic castration resistant prostate cancer
Winston Vuong1, Oliver Sartor2, Sumanta K Pal1
1 Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
2 Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
Correspondence Address:
Sumanta K Pal
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1008-682X.127812
|
|
|
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals. However, from 2010 onwards, 5 additional therapies have been approved on the basis of showing a survival benefit in phase III studies. These agents include sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and (most recently) radium-223. Amongst radiopharmaceuticals currently used for advanced prostate cancer (e.g. samarium-153 and strontium-89), radium-223 possesses several unique properties. As an alpha-emitting compound, the agent produces a high-energy output over a short range, facilitating selective destruction of tissue within the bone in the region of osteoblastic lesions while sparing surrounding normal tissue. The current review will outline biological rationale for radium-223 and also provide an overview of preclinical and clinical development of the agent. Rational sequencing of radium-223 and combinations, in the increasingly complex landscape of mCRPC will be discussed, along with factors influencing clinical implementation. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
